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Effects of Iongterm beabnent with Montelukast in patients with mild 
cystic fibrosis 
S. Schmitt Groh61, O. Eickmeier 2,C. Nauj  oks 1, R. Schubert 2,S. Zielen 2
~ChiMren's Hospital Medical Center; University of Bonn a~u] 2Department of 
Pediatric PuIrrmnaty, University Hospital of Fr nkfurt, Germany 
Previously we  have provided evidence that Montelukast reduces eosinophilic 
inf lammation ha cystic fibrosis but could not report a significant cl inical benefit after 
a 21 day treatment course with Montelukast A. 
AIM: The aim of the present study was to evaluate the clinical and anti 
inflammatory effects of long term treatment with Montelukast (6 to 14 years, 
5 mg; > 14 years, 10 mg) by fol low up of the original study population. 
METHODS:  Pulmonary function tests (FEVp MEF~),  total eosinophil count, 
Immunogloblul ine (Ig) E as wel l  as sputum samples/pbaryngeal swabs were 
evaluated at the begimaing of the study (PRE) and after a long'term treatment course 
(POST). 
RESULTS: Fol low up data was available from 15 of the original sixteen patients 
(9 boys/6 gkls); age POST median 12.5 years (8 to 18.5 years) with a median 
observation period of 3.67 y (2 .714.84 y). Overall there was no significant 
improvement of FEV 1 (PRE/POST median 92.5/86 %) or MEFg~ (PRE/POST 
median 58.5/61 %) and total eosinophil count (PRE/POST median 150/150 ~tl). IgE 
(PRE/POST median 38.2/43.9 kU/L) did not change significantly, but 6 of the 
originally 7 cbr onically Pseudomot~s aeruginosa infected patients were repeatedly 
negative (p< 0.031). 
CONCLUSION: Montelukast might support prevention of chronic Pseudomonas 
aeruginosa colonization in mild cystic fibrosis. 
ASchmitt Groh6 S et al. Ant i  i lRlammatory effects of montelukast in mild cystic 
fibrosis. Area Al lergy Asthma Immunol  2CO2; 89:599 605 
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Insulin Glargine (IG) for therapy of Cystic Fibrosis Related Diabetes 
(CFRD) and Impaired Glucose Tolerance (IGT) in Cystic Fibrosis (CF) 
paSents (pts) 
L. Minicucci, A. De  Alessandri, R. Casciar o, O. Bur lando, F. Lugani, E. Poggi, R. 
Lorini 
Department of Pediatrics, Institute GGaslini, Italy 
The aim of study was to investigate the efficacy and safety of IG ha a group of CF 
pts with a diagnosis of CFRD or IGT. The study group was composed by 6 CFRD 
pts (Group A: 5 females, mean age 26 yrs, range 19 34 yrs, DM mean duration 11 
yrs, range 6 18), 6 CF pts without lasting hyperglycemia and DM on the basis of 
OGTT (Group B : 4 females, mean age 23 yrs, range 14 34) mad 3 CF pts with IGT 
(Group C: 1 female, mean age 25 yrs, range 19 31). A single daily dose of IG was 
performed (mean dose for Group A was 0,3 U/Kg, Group B 0,2 U/Kg, Group C 
0,1 U/kg). Group A, as before IG therapy, received insulin regular or rapid analogue 
before meals and IG took the place of insulin intermediate; Group B and Group C 
had never been treated before with ins~alin. Data about HbA lc, BMI,  frequency of 
hypoglycaemia mad compliance to the therapy were collected at the start of IG 
therapy and after 3 months. In all pts no significant difference was found in HbA lc  
(Group A:  9.6% vs 9.2%; Group B: 7% vs 7,47%; Group C: 6,76% vs 6,74%) mad 
BMI  (Group A: 21 vs 21,5; Group B: 16,68 vs 17,2; Group C: 18,17 vs 18,55). 
Hypoglycemia frequency did not change ha Group A and no hypoglycemia episodes 
were observed in Group B and C. Compliance improved in Group A and was very 
good in Group B and C. 
Even it" IG did not improve metabolic ontrol in our patients, it appeared safe and 
wel l  accepted mad it seemed to have a good impact on nutritional status. Indeed the 
lack of significance ha BMI  increment might depend on the low number of pts and 
on the short follow up. We are performing an Ital ian multicenter case control study 
in IGT patients to investigate it" IG can improve CF pr oguosis. 
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Colistin intravenously is a safe and effective treatment of multidrug- 
resistant microorganisms in cysSc fibrosis 
A. Rosenvinge 1,T. Pressler 1, N. HNby 2 
~Department of Paediatrics, RigshospitaIet, National University Hospital, 
Copenhagen, De~nadr, 2Department of Microbiology, Rigshospitalet, National 
University Hospital, Copet~u~getg Det~natk 
Introduct ion:  Mult idrug resistant microorganisms are an important and growing 
issue in the care of patients with cystic fibrosis (CF). Colistin, also known as 
Polymyxin E, has been of interest because of the significant activity against 
multiresistant pseudomonas aemginose and the low resistance rates to it. 
A im:  To determine the efficacy and safety of treatment with intravenous Colistin in 
patients with CE 
Pa l lents /methods:  Thirteen CF patients were treated with 6 MIE  Colistin 
intravenously once a day for 14 days. Spirometry was undertaken and Colistin 
levels were measured in serum before and 1.5 hours after the infusion. 
Statistics: The changes in forced expiratory volume (FE%I)  and forced vital 
capacity (FVC) before and after Colistin treatment were compared using the 
Wilcoxons matched paired signed ranks test. Averages are expressed as median 
values. 
Results: FEV1 increased significantly by 4.1% after the treatment (P<0.05). The 
FVC increased 7,6% (p<0.01) 
Conclusion: The Colistin treatment was wel l  tolerated by all CF patients with no 
signs of toxicity. Yet, one patient had an allergic reaction within infusion of the first 
dose. Colistin is an effective and safe intravenous antibiotic treatment of multi&~ag 
resistant microorganisms in patients with cystic fibrosis. 
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Guidelines for human embryonic stem cell research in CF: Two 
countries, two similar views 
M.J. M61an~on l, F. Baylis ~ , N. Ram 2, M.  De  Br  aekeleer ~ 
iUniversitd du Qudbec, Chicoutimi, Canada; 2Dallu~usie University, Halifax, 
CatuMa; SFacuItd de Mddecine, Brest, Fratwe 
Stem cells are undifferentiated cells capable of selErenewal, differentiation and 
growth. Human Embryonic Stem Cells (bESC) have a tremendous potential in cell 
therapy for various diseases, for example cystic fibrosis (CF). They can be derived 
from embryos created by IVF and no longer wanted for reproductive purposes. As 
well ,  they can be derived from embryos created by Somatic Cell Nuclear Transfer 
(commonly known as cloning). For different reasons, both of these sources of bESC 
are ethically controversial. This presentation summarizes current policy for bESC 
research in two western countries. Canada (2CO2, 2004) and Switzerland (2CO4, 
2CO5) have been selected for comparative ethical analysis with particular attention 
to points of convergence and divergence. Both countries: anthorize the derivation of 
bESC under strict conditions, because of the potential scientific and therapeutic 
benefits; are concerned with the ethical dimensions of creating bESC; attentive to 
the ethical arguments about the moral status of the human embryo; prohibit the 
creation of embt3,os for research and the use of cloning for stem cell research; and 
impose several other conditions for using ESC. Each country: used a different 
policy making process (parliamentary prccess vs. referendum); has different 
national policy implementation practices. 
Canada and Switzerland are at the conservative end of the spectrum of countries that 
allow for bESC research. Diseases like CF could benefit of bESC research and 
eventual stem cell therapeutics. Hence the importance of reviewing policies and 
practices in a global context as this might benefit patients with CF disease. 
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